Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Spineway S.A. (ALSPW.PA)
EUR0.13
0.00 (-1.05%)
FR PAR Healthcare Medical - Specialties
Address
7, allEe Moulin Berger 69130
Ecully, FR
Ecully, FR
CEO
Stéphane Le Roux
Website
spineway.com
IPO
2013-02-13
ISIN FR001400N2P2
Description
Spineway SA designs, develops, and markets a range of surgical implants for spine in France. The company offers posterior fixation, including posterior osteosynthesis systems and minimal invasive posterior osteosynthesis systems; interbody fusion products, such as lumbar cage twin peaks tlif curved and oblique; motion preservation products; and biomaterials. It also exports its products. The company was incorporated in 2005 and is headquartered in Ecully, France.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR0.13
0.00 (-1.05%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
107.2K
Beta
0.24
Float Shares
833.0K
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.46% | -6.04% | -18.27% | -18.38% | -15.19% | -14.08% | +3.00% | -99.99% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.13
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.99
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%+4.0% Q4'25: +25.6% (vs Q4'23)
-
EPS growth Medical - Specialties: +10.1%+51.5% ★ Q4'25: +100.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-12.3% Q4'25: +8.0% (vs Q4'23)
-
EBIT margin Medical - Specialties: +12.6%-17.2% Q4'25: -14.0% (vs Q4'23)
-
ROIC Medical - Specialties: +6.6%-10.1% Q4'25: -15.8% (vs Q4'23)
-
Share dilution Medical - Specialties: 0.0%-87.3% ★ Q4'25: +49,658.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-1.13× Q4'25: -0.77× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.72M
est: 5.07M (-6.9%)
|
6.64M
est: 7.26M (-8.5%)
|
5.22M
est: 5.07M (+2.9%)
|
5.70M
est: 6.09M (-6.5%)
|
5.09M
est: 6.19M (-17.7%)
|
9.59M
est: 9.34M (+2.7%)
|
6.91M
est: 6.70M (+3.2%)
|
5.59M
est: 6.09M (-8.3%)
|
3.38M
est: 6.60M (-48.8%)
|
4.29M
est: 6.48M (-33.7%)
|
7.43M
est: 6.45M (+15.2%)
|
11.95M
est: 12.90M (-7.4%)
|
12.43M
est: 14.90M (-16.6%)
|
13.20M
13.20M – 13.20M
-11.4% YoY
|
14.50M
14.50M – 14.50M
+9.8% YoY
|
| EBITDA |
533.7K
est: -1.96M (+127.3%)
|
200.1K
est: 114.4K (+74.9%)
|
-1.26M
est: -272.7K (-363.4%)
|
-1.33M
est: -2.30M (+42.3%)
|
-1.48M
est: -2.37M (+37.3%)
|
-102.0K
est: -2.42M (+95.8%)
|
-3.17M
est: -2.53M (-25.2%)
|
-1.55M
est: -2.30M (+32.8%)
|
-1.32M
est: -2.21M (+40.4%)
|
-1.05M
est: -2.20M (+52.5%)
|
-2.76M
est: -2.50M (-10.5%)
|
-5.58M
est: -4.25M (-31.3%)
|
-1.36M
est: -4.91M (+72.4%)
|
-4.35M
-4.35M – -4.35M
+11.4% YoY
|
-4.77M
-4.77M – -4.77M
-9.8% YoY
|
| EBIT |
135.4K
est: -2.49M (+105.4%)
|
-284.6K
est: 286.0K (-199.5%)
|
-1.83M
est: -258.7K (-608.1%)
|
-2.14M
est: -2.92M (+26.7%)
|
-2.36M
est: -1.86M (-26.4%)
|
-845.0K
est: -3.79M (+77.7%)
|
-3.78M
est: -3.22M (-17.6%)
|
-2.89M
est: -2.92M (+1.1%)
|
-1.96M
est: -2.96M (+33.8%)
|
-1.54M
est: -2.95M (+48.0%)
|
-3.33M
est: -3.18M (-4.7%)
|
-6.28M
est: -5.26M (-19.4%)
|
-2.13M
est: -6.08M (+64.9%)
|
-5.39M
-5.39M – -5.39M
+11.4% YoY
|
-5.92M
-5.92M – -5.92M
-9.8% YoY
|
| Net Income |
409.9K
est: 40.21M (-99.0%)
|
-51.4K
est: 586.3K (-108.8%)
|
-1.67M
est: -35.0K (-4,666.8%)
|
-1.69M
est: -59.43M (+97.2%)
|
-2.69M
est: -1.71M (-57.0%)
|
-965.0K
est: -4.06M (+76.2%)
|
-4.12M
est: -693.0K (-495.1%)
|
-2.88M
est: -6.79M (+57.7%)
|
-14.05M
est: -3.12M (-350.8%)
|
-1.58M
est: -3.10M (+49.0%)
|
-3.14M
|
-3.86M
est: -18.47M (+79.1%)
|
-2.24M
est: -2.45M (+8.6%)
|
-2.49M
-2.49M – -2.49M
-1.6% YoY
|
-2.49M
-2.49M – -2.49M
+0.0% YoY
|
| SGA |
—
est: 915.1K (-100.0%)
|
1.96M
est: 1.92M (+2.3%)
|
2.38M
est: 1.43M (+66.9%)
|
2.56M
est: 1.08M (+137.9%)
|
2.32M
est: 2.70M (-14.3%)
|
3.51M
est: 3.64M (-3.7%)
|
3.61M
est: 1.18M (+205.0%)
|
2.52M
est: 1.08M (+134.1%)
|
165.0K
est: 1.17M (-85.9%)
|
47.0K
est: 2.81M (-98.3%)
|
358.0K
est: 1.17M (-69.4%)
|
9.13M
est: 3.32M (+174.9%)
|
5.40M
est: 3.84M (+40.8%)
|
3.40M
3.40M – 3.40M
-11.4% YoY
|
3.73M
3.73M – 3.73M
+9.8% YoY
|
| EPS |
4,879.56
est: 0.14 (+3,383,783.5%)
|
-612.05
|
-18,939.98
est: -0.30 (-6,340,703.5%)
|
-19,153.84
est: -0.22 (-8,855,119.6%)
|
-55,693,581.78
est: -0.29 (-19,311,227,979.1%)
|
-19,950,382.47
est: -0.13 (-15,495,442,595.1%)
|
-53,440,443.18
est: -0.07 (-74,119,893,353.5%)
|
-5,134,980.72
est: -0.02 (-20,772,575,628.2%)
|
-383,876.48
|
-9,527.17
|
-5.48
|
-0.13
est: -0.52 (+75.0%)
|
-0.06
est: -0.07 (+8.6%)
|
-0.07
-0.07 – -0.07
-1.6% YoY
|
-0.07
-0.07 – -0.07
+0.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-21.12M
OE per share TTM
-75,417.40
Owner's Yield
-454.52%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
20.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Shares Outstanding
833.0K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Philippe Laurito | Director & Chief Technology Officer of Spineway Inc. | 121.3K | male |
| Stephane Le Roux | Chairman, Chief Executive Officer & President | 121.3K | male |
| Guillaume Bertet | Controller | — | male |
| Jon R. Luedke | Chief Executive Officer of Spineway Inc. | — | male |
| Agnès Mignani | Human Resources Manager | — | female |
| Mickaël Battisti | Controller | — | male |
| Sandrine Carle | Deputy Chief Executive Officer | — | female |
| Marie-Christelle Desmolles | Controller | — | female |
| David Siegrist | Financial Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALSPW.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
